1. Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

2. Third-Generation EGFR TKIs

5. EGFR Inhibitors Following Progression on EGFR-Directed Therapy Preliminary Efficacy Comparison

6. Antiangiogenic Agents in Advanced NSCLC

9. First-line Therapy in Advanced NSCLC

14. Targeting MET in Advanced NSCLC

15. Global Phase 3 Trial (METLung)
Global Phase 3 Trial (METLung)* of Onartuzumab Plus Erlotinib in NSCLC Trial Design

16. METLung Trial Overall Survival Results

17. Crizotinib in Advanced MET-amplified NSCLC Patient Eligibility: NSCLC MET Amplification Cohort

19. Characteristics of Patients With ALK-Positive Disease; Second- Generation ALK Inhibitors

21. ASCEND-1 Trial: Ceritinib in ALK-Positive Advanced NSCLC Best Percentage Change From Baseline

22. Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

24. Abbreviations

25. Abbreviations (cont)

26. References

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)